Last reviewed · How we verify
PADRE-CMV fusion peptide vaccine
PADRE-CMV fusion peptide vaccine is a Biologic drug developed by City of Hope Medical Center. It is currently in Phase 1 development.
At a glance
| Generic name | PADRE-CMV fusion peptide vaccine |
|---|---|
| Sponsor | City of Hope Medical Center |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PADRE-CMV fusion peptide vaccine CI brief — competitive landscape report
- PADRE-CMV fusion peptide vaccine updates RSS · CI watch RSS
- City of Hope Medical Center portfolio CI
Frequently asked questions about PADRE-CMV fusion peptide vaccine
What is PADRE-CMV fusion peptide vaccine?
PADRE-CMV fusion peptide vaccine is a Biologic drug developed by City of Hope Medical Center.
Who makes PADRE-CMV fusion peptide vaccine?
PADRE-CMV fusion peptide vaccine is developed by City of Hope Medical Center (see full City of Hope Medical Center pipeline at /company/city-of-hope-medical-center).
What development phase is PADRE-CMV fusion peptide vaccine in?
PADRE-CMV fusion peptide vaccine is in Phase 1.